Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2003Expert Opinion on Investigational Drugs

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

Daniel J. Drucker
Daniel J. DruckerUniversity of Toronto

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Daniel J. Drucker (2003) studied this question.

synapsesocial.com/papers/6a08aa92280cd4e998e8d799https://doi.org/10.1517/13543784.12.1.87
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor−/− Mice*1998 · 91 citations
  2. 2Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.1999 · 337 citations
  3. 3Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.1987 · 888 citations
  4. 4Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs2002 · 146 citations
  5. 5Targeting Dipeptidyl Peptidase IV (CD26) Suppresses Autoimmune Encephalomyelitis and Up-Regulates TGF-β1 Secretion In Vivo2001 · 136 citations